Ankylosing spondylitis is a common, highly heritable inflammatory arthritis affecting primarily the spine and pelvis. In addition to HLA-B*27 alleles, 12 loci have previously been identified that are associated with ankylosing spondylitis in populations of European ancestry, and 2 associated loci have been identified in Asians. In this study, we used the Illumina Immunochip microarray to perform a case-control association study involving 10,619 individuals with ankylosing spondylitis (cases) and 15,145 controls. We identified 13 new risk loci and 12 additional ankylosing spondylitis-associated haplotypes at 11 loci. Two ankylosing spondylitis-associated regions have now been identified encoding four aminopeptidases that are involved in peptide processing before major histocompatibility complex (MHC) class I presentation. Protective variants at two of these loci are associated both with reduced aminopeptidase function and with MHC class I cell surface expression.
Inflammatory arthritis in ankylosing spondylitis causes pain and stiff ness and progressively leads to new bone formation and ankylosis (fusion) of affected joints. It affects 0.55% of populations of European ancestry (herein termed Europeans) 1 and 0.23% of Chinese 2 , but is uncommon in Africans and Japanese, mostly owing to the low preva lence in these ancestry groups of HLA-B*27, the major genetic variant associated with ankylosing spondylitis. Whereas effective treatments are available that suppress inflammation and improve symptoms, there are not yet any treatments that have been shown to robustly slow the rate of ankylosis or induce disease remission.
Ankylosing spondylitis is highly familial (sibling recurrence risk ratio of >52) 3 and heritable (h 2 > 90%) 4 . It is two to three times more preva lent in men than in women, and men tend to be more severely affected. More than 80% of cases are positive for the HLA-B*27 allele, but only a minority of HLA-B*27 carriers develop ankylosing spondylitis (1-5%). The low proportion of HLA-B*27 carriers who develop ankylosing spondylitis reflects the fact that numerous other non-HLA-B*27 variants are likely to influence disease susceptibility 3 . In addition to HLA-B*27, 12 loci have previously been confirmed to be associated with ankylosing spondylitis in Europeans (ANTXR2, CARD9, ERAP1, IL12B, IL23R, KIF21B, PTGER4, RUNX3, TBKBP1, TNFRSF1A and chromosomes 2p15 and 21q22) [5] [6] [7] , and 2 loci have recently been reported in Han Chinese (HAPLN1EDIL3 and ANO6) 8 .
The Immunochip Consortium has developed a custom microarray SNP genotyping chip (the Immunochip), the design of which has been informed by available genomewide association study (GWAS) and deep sequencing data from various autoimmune and inflamma tory diseases to provide a costeffective platform for immunogenetic studies 9, 10 . Genetic data from ankylosing spondylitis, psoriasis, A r t i c l e s TNFRSF1A and chromosomes 2p15 and 21q22 (Table 1) . At PTGER4, the previously associated SNP (rs10440635) also showed moderate association in the current study (P = 3.0 × 10 −5 ; imputed). No SNPs at the ANTXR2 locus were included on the Immunochip.
We observed little evidence of association with the two previously reported loci in Han Chinese, either in Europeans, East Asians (Chinese, Taiwanese and Koreans) or in the combined data set (P > 0.05) 8 . To increase power for these variants, we genotyped a total of 2,998 East Asian cases and 5,547 East Asian controls. No associa tion was seen (P > 0.05) for either rs4552569 (chromosome 5q14, between HAPLN1 and EDIL3) or rs17095830 (chromosome 12q12, ANO6) (Supplementary Table 3 ). rs4552569 showed only nominal significance in Europeans (P = 0.02). rs17095830 was not directly typed on the Immunochip, but, in a previous GWAS 6 , no association was observed with this SNP (P > 0.1).
Genomewide significance was seen at 13 loci not previously known to be associated with ankylosing spondylitis ( Table 1) . The strongest asso ciation at each locus was with a common variant (minor allele frequency (MAF) > 5%), but several associations were also seen with rare variants (MAF < 1%) at these loci, including in the genes CARD9, IL23R, LNPEP and TYK2. Both rare variants in IL23R were nonsynonymous coding variants, whereas the CARD9, TYK2 and LNPEP variants were located at exonintron boundaries and were predicted to influence splicing.
In total, 24.4% of the heritability of ankylosing spondylitis is now explained: 4.3% from loci other than HLA-B and 20.1% due to HLA-B*27 itself.
IL-23 pathway genes
Genetic studies provided the first evidence that interleukin (IL)23 is involved in the pathogenesis of ankylosing spondylitis, and vari ants in several genes involved in the IL23 proinflammatory cytokine pathway have been shown to be associated with the disease. This study adds to that list, with loci containing TYK2, IL6R and IL27 achieving genomewide significance.
IL6 signaling through IL6R has diverse proinflammatory effects. rs4129267, the most strongly associated IL6R SNP in this study, is also associated with asthma 11 but with the opposite direction of associa tion to ankylosing spondylitis. The allele associated with risk of anky losing spondylitis at this SNP is strongly associated with lower serum concentrations of the soluble form of the IL6 receptor (sIL6R), with each allele associated with a 1.4fold variation in serum IL6R conc netrations 12 . We found that sIL6R concentrations varied strongly by rs4129267 genotype, both overall and separately, in cases and controls (Fig. 1) . Overall, homozygous carriers of the T allele at rs4129267 had sIL6R concentrations 73% higher than homozygous carriers of the C allele (28.9 versus 16.7 ng/ml; P = 7.8 × 10 −17 ). This SNP has previ ously been associated with serum Creactive protein (CRP) concen trations at genomewide significance; in the current study, serum CRP concentrations were 30% higher in cases homozygous for the T allele than in cases homozygous for the C allele (19.2 versus 14.8 mg/l).
At IL23R, we previously identified two independent disease associated haplotypes 6 tagged by rs11209026 and rs11209032. Here, after conditioning on rs11209026, the strongest association was with 
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A r t i c l e s rs12141575 (odds ratio (OR) = 1.15; P = 9.4 × 10 −11 ); this SNP is in strong linkage disequilibrium (LD) with rs11209032 (r 2 = 0.993) and also with rs1495965, which has been reported to be associated with Behçet's disease 13, 14 . Behçet's disease is complicated by sacroiliitis resembling ankylosing spondylitis in up to 10% of cases 15 . Six loci showed suggestive association (5 × 10 −8 < P < 5 × 10 −7 ), including a region on chromosome 2q11 encoding IL1R2 and IL1R1. Conditional analyses showed that there were two separate signals at this locus ( Table 2) , one in each gene. Both genes encode receptors for the cytokine IL1, which, among diverse proinflammatory functions, also promotes T helper 17 (T H 17) lymphocyte differentiation.
Aminopeptidase genes
We previously identified a strong association between ERAP1 and ankylosing spondylitis 5 that is restricted to HLA-B*27-positive disease 6 . This observation was replicated here ( Table 3 and Supplementary Figs. 3 and 4) , with strong interaction observed in the European cases between HLA-B*27 and both independently associated ERAP1 haplotype-tagging SNPs (rs30187: β = 0.390, P = 2.9 × 10 −11 ; rs10045403: β = −0.282, P = 9.3 × 10 −6 ; Supplementary Table 4) . We observed no evidence of epistasis between HLA-B*27 and rs30187 (or other SNPs in ERAP1) in the East Asian samples, probably because of inadequate statistical power. In this analysis, we had 35% power to detect an association at a significance level of P < 0.05 with the observed allele frequency of rs30187 in controls and the effect size observed in the overall analysis. The low power to detect a major effect at rs30187 in HLA-B*27-positive East Asian samples suggests that the power to detect an interaction would be quite small. The observed OR (95% confidence interval (CI)) in HLA-B*27-positive subjects at rs30187 was 0.73 (0.53-1.03) compared to 1.20 (0.89-1.61) in HLA-B*27-negative subjects. Although these analyses did not detect significant interaction (P > 0.05), they are consistent with an interac tion between rs30187 and HLA-B*27, where rs30187 is only associated in HLA-B*27-positive disease. This finding warrants further explora tion with larger sample sizes in East Asian populations.
LNPEP and ERAP2 are both members of the endoplasmic reticulum (ER) aminopeptidase family and have substantial sequence homology with ERAP1. They are both encoded on chromosome 5q15, imme diately centromeric to the ERAP1 locus. A previous study, which did not control for the association of ERAP1 with ankylosing spondylitis, observed no association of an ERAP2 lossoffunction variant with ankylosing spondylitis 16 . Other studies have identified associations with ERAP2 but have not dissected them from the known associations of ERAP1 SNPs 5, 17 . Here, controlling for the association of ERAP1 with ankylosing spondylitis, two functionally important SNPs in ERAP2 were found to be associated with ankylosing spondylitis: rs2549782, which leads to a change in ERAP2 catalytic activity 18 , and rs2248374, where the protective G allele causes complete loss of ERAP2 mRNA and absence of ERAP2 protein 19 . In the European samples, control ling for the association with ERAP1, we identified SNPs in ERAP2 and LNPEP that were associated with ankylosing spondylitis (lead SNP, rs2910686: OR = 1.2, P = 4.5 × 10 −17 ; Supplementary Fig. 3b ). Because the association of ERAP1 variants was restricted to HLA-B*27-positive ankylosing spondylitis, analyzing ERAP2 and LNPEP SNPs in HLA-B*27-negative cases and controls produced simi lar results to analyses of the combined (HLA-B*27-positive and HLA-B*27-negative) cases and controls when the association with ERAP1 was controlled for. Thus, we observed association with ERAP2 SNPs in HLA-B*27-negative ankylosing spondylitis cases (rs2910686: OR = 1.19, P = 2.13 × 10 −5 ). To investigate the possibility that this finding might be an artifact caused by the strong LD between the ERAP2 locus and HLA-B*27 in cases, we tested association at this locus in a multivariate analysis, controlling in the one analysis for association of the two ankylosing spondylitis-associated ERAP1 hap lotypes (tagged by rs30187 and rs10045403), their interaction with HLA-B*27 and HLA-B*27 itself. In this analysis, association with rs2910686 was robust (P = 6.6 × 10 −8 ), suggesting that ERAP2LNPEP is independently associated with ankylosing spondylitis. Haplotype counts for rs2910686 and rs30187 in both HLA-B*27-positive and HLA-B*27-negative cases are shown in Table 3 . IL-6R concentrations were determined in cases and controls who were homozygous for either the T or C allele at the rs4129267 SNP. In both cases and controls, individuals homozygous for the C allele showed significantly lower concentrations of circulating IL-6R. ***P < 0.0001; NS, not significant. Bars represent mean ± s.e.m. 
A r t i c l e s
In addition to these ERAP1 and ERAP2 associations, we observed genomewide significant association of SNPs on chromosome 17q21 around the gene NPEPPS, which encodes puromycinsensitive ami nopeptidase (rs9901869: OR = 1.14, P = 6.0 × 10 −15 ) ( Supplementary  Fig. 5 ). The NPEPPS protein localizes to the cytoplasm and is thought to be involved in processing proteasomederived peptides before their transport to the endoplasmic reticulum and presentation by human leukocyte antigen (HLA) class I molecules 20 . Association had previ ously been reported at this locus and was ascribed to TBKBP1 or TBX21. Here SNPs mapping to NPEPPS and TBX21 were independ ently associated with ankylosing spondylitis, and conditional analysis suggested that there are at least two independent signals at this locus. When conditioning on rs9901869, SNP rs11657479 in the 3′ UTR of TBX21 remained significantly associated with ankylosing spondylitis (OR = 1.09; P = 1.8 × 10 −3 ). The data did not allow us to determine whether TBKBP1 or TBX21 was primarily associated with ankylos ing spondylitis, but both represent attractive candidates. TBKBP1 is a component of the tumor necrosis factor (TNF) signaling pathway, and TBX21 is a transcription factor that influences the differentiation of T helper 1 (T H 1) and natural killer (NK) cells 21 .
Genes influencing lymphocyte activation and differentiation
It has recently been shown that cell type-specific trimethylation of his tone H3 at lysine 4 (H3K4me3) chromatin marks can inform the fine mapping of associated SNPs to identify causal variation 22 . We therefore tested all ankylosing spondylitis-associated SNPs against H3K4me3 chromatin marks in different cell lines from the Encyclopedia of DNA Elements (ENCODE) Project 23 . This analysis showed a strong enrich ment of diseaseassociated SNPs associated with H3K4me3 chromatin marks in cells of immune origin (Supplementary Fig. 6 ).
Because of this association and taking into account the likely pathogenic role of T lymphocytes in ankylosing spondylitis and the involvement of several genes associated with ankylosing spondylitis in Tlymphocyte differentiation, we tested association of the SNPs for ankylosing spondylitis with CD4 + and CD8 + T cell counts in a previously published GWAS data set 24 . Association (P < 0.005) was seen between CD8 + lymphocyte counts and ankylosing spondylitisassociated SNPs in the loci harboring the genes IL7R, RUNX3 and ZMIZ1 (Supplementary Table 5 ). Association was also observed between SNPs in EOMES and CD8 + lymphocyte counts, but these were not the same EOMES SNPs that were associated with ankylosing spondylitis. We also showed association of the genes SH2B3 and BACH2 with both ankylosing spondylitis and CD4 + lymphocyte counts (Supplementary Table 5 ). We previously showed that CD8 + lymphocyte counts are lower in ankylosing spondylitis cases than in healthy age and sexmatched controls 6 . In contrast, in this study, we found that ankylosing spondylitis cases not on biological therapy had similar CD4 + lymphocyte counts as agematched controls (Supplementary Fig. 7 ).
HLA Region
After SNP imputation in the MHC region, rs116488202 was found to tag HLA-B*27 more accurately in both Europeans and Asians than our previously reported tagging SNP rs4349859 and also rs13202464, reported to tag HLA-B*27 in Asian populations 8 Table 6 ). The expected strong association was observed with HLA-B*27 (OR = 46; P < 1 × 10 −100 ) (Supplementary Fig. 8 ). Risk of ankylosing spondylitis was further increased in HLA-B*27 homozygotes; HLA-B*27 homozygosity was more prevalent in HLA-B*27-positive cases than in HLA-B*27-positive controls (OR = 2.07; P = 0.0025).
(Supplementary
Controlling for association with HLA-B*27, there was residual signal with SNPs near HLA-A and HLA-B (Fig. 2) . The residual signal at HLA-B may reflect either imperfect HLA-B*27 tagging by rs116488202 or association of other HLA-B alleles with ankylosing spondylitis. No other individual non-HLA-B*27 allele was associated with ankylosing spondylitis, although this may represent imperfect HLA-B imputation using single SNPs.
The most strongly associated SNP near HLA-A, rs2394250, tags the classical allele HLA-A*0201 (Supplementary Table 7) . Association of the HLA-A*0201 allele was independent of HLA-B*27 genotype, present in both HLA-B*27-positive (OR = 1.21, P = 6.5 × 10 −12 ; conditioning on rs116488202) and HLA-B*27-negative (OR = 1.36, P = 3.2 × 10 −13 ) disease (Supplementary Table 7b) . No significant correlation was noted between HLA-B*27 and SNPs tagging 
Overlap with other immune-mediated diseases
Considering the loci associated with ankylosing spondylitis in this study, we found substantial overlap with other immunemediated diseases ( Fig. 3 and Supplementary Table 8) , notably, inflammatory bowel disease (either Crohn's disease or ulcerative colitis) and celiac disease. Ankylosing spondylitis-associated loci were associated with the same SNP in the same direction of association at 12 loci shared with Crohn's disease, at 11 loci shared with ulcerative colitis and at 6 of 7 loci shared with celiac disease. Overlap of associated loci with other diseases was not as marked, including for rheumatoid arthritis (one concordant, one discordant), psoriasis (two concordant), multi ple sclerosis (three concordant, three discordant) and type 1 diabetes (two concordant, two discordant).
Refinement of disease associations and secondary signals
In the design of the Immunochip, eight loci already known to be associated with ankylosing spondylitis were selected for fine mapping. Compared with available ankylosing spondylitis GWAS data, the cur rent study had greater marker density at these loci and larger sample size (from 3,023 cases and 8,779 controls to 10,619 cases and 15,145 controls). Nonetheless, for most loci studied, the diseaseassociated region was not substantially narrowed; less than 10% narrowing of the region was observed for four of the eight loci that were fine mapped (Supplementary Table 9 ). This suggests that, for many loci associated with common variants, the extent of LD at the locus will be too great to permit substantial refinement of the locus using sample sizes and marker densities of the magnitude employed here.
Two or more independent signals were identified at 12 of the 25 genomewide significant loci (P < 5 × 10 −4 ; Table 2 and Supplementary Fig. 9 ), including 1 locus (ERAP1 on chromosome 5q15) with 3 associated haplotypes (Supplementary Fig. 3 ). This is a similar proportion to that found in celiac disease (13 of 36 loci) 10 . Taken together, these secondary signals contribute 0.75% of the herit ability of ankylosing spondylitis (Supplementary Table 10 ).
Rare variants
Because of the likelihood of population stratification affecting rare variant associations, rare variant associations (MAF < 1%) were only tested on a reduced sample subset of indi viduals from the UK (7,447 cases and 11,479 controls). Considering loci with common variant associations achieving genomewide significance, we identified six that harbored rare SNPs that were disease associated (P < 5 × 10 −3 ; Supplementary Table 11 ). These associations remained significant after con ditioning on the common variants, and vari ants at three loci (IL23R, TYK2 and KEAP1) remained significant after controlling for the number of variants studied per locus. Four loci had exonic rare variant associations in the absence of a common variant association (P < 5 × 10 −5 ) (KLKB1, RAD50, PRDM1 and DYRK4; Supplementary Table 11b). The rare variant with the largest effect was a predicted splicesite variant in TYK2 (rs280518: OR = 7.7, P = 0.002).
Comparisons across ancestry groups
The power of our East Asian casecontrol cohort was much lower than for our European cohort; nonetheless, at least nominal association (P < 0.01) was detected in East Asians at 13 of the 23 loci for which we identified associations at genomewide significance in the overall data set ( Table 1) .
At some loci, association was seen in both East Asians and Europeans but with different SNPs. At IL23R, the primary associ ated variant in Europeans, rs11209026, was not polymorphic in East Asians, as we and others have previously reported 25 . However, asso ciation was observed at IL23R with a lowfrequency nonsynonymous SNP in East Asians (rs76418789: p.Gly149Arg, OR = 1.5, P = 8.2 × 10 −4 ). The minor, protective allele was predicted to be deleterious by both SIFT 26 and PolyPhen analysis 27 . The same SNP was also nomi nally associated with ankylosing spondylitis in Europeans (P = 0.01). The MAF of rs76418789 was ~10 times greater in East Asians than in Europeans (East Asians, 3.7%; Europeans, 0.34%). Of the other loci associated with ankylosing spondylitis in Europeans but not in East Asians, only at BACH2 was the key associated variant present at a much lower frequency in East Asians (rs17765610; MAF of 11.8% in Europeans and 1.8% in East Asians), suggesting that, at most loci with discordant association between ancestry groups, this was not due to differences in the population frequency of the associated SNP.
At PTGER4, association in Europeans peaked 155 kb 5′ of the gene (peak associated SNP, rs12186979: OR = 1.1, P = 5.4 × 10 −6 ), whereas the peak of association in East Asians was in intron 2 of the gene (rs13354346: OR = 1.3, P = 1.5 × 10 −5 ) (Supplementary Fig. 5 ).
DISCUSSION
This study confirmed the association of 12 of the 13 previously reported loci associated with ankylosing spondylitis in Europeans and identified 13 additional loci at genomewide significance. We found no inde pendent support for two loci previously reported to be associated with ankylosing spondylitis in Han Chinese, suggesting that the original RUNX3  IL23R  IL23R-IL12RB2  GPR25-KIF21B  PTGER4  ERAP1-ERAP2-LNPEP  ERAP1-ERAP2-LNPEP  IL12B  IL12B  CARD9  LTBR-TNFRSF1A  NPEPPS-TBKBP1-TBX21   IL6R  FCGR2A  UBE2E3  GPR35  NKX2-3  ZMIZ1  SH2B3  GPR65  IL27-SULT1A1  TYK2  ICOSLG  EOMES  IL7R  UBE2L3   21q22   rs6600247  rs11209026  rs12141575  rs41299637  rs12186979  rs30187  rs2910686  rs6871626  rs6556416  rs1128905  rs1860545  rs9901869   rs4129267  rs1801274  rs12615545  rs4676410  rs11190133  rs1250550  rs11065898  rs11624293  imm_16_28525386  rs35164067  rs7282490  rs13093489 A r t i c l e s associations of these loci may have been false positives. Additional associated haplotypes were identified at 13 loci, increasing the total number of distinct ankylosing spondylitis associations to 43. These findings highlight the role of some major biological pathways in the pathogenesis of ankylosing spondylitis, including the IL23 pathway, gut immunity, Tlymphocyte differentiation or activation, and peptide processing before HLA class I presentation.
We identified three new ankylosing spondylitis-associated genes (TYK2, IL27 and IL6R) with known effects on the IL23 pathway. TYK2 is a member of the Janus kinase family of intracellular signaling proteins and is involved in signal transduction from IL23R, as well as other cytokine receptors, including those in interferon (IFN)α, IFNβ, IL6, IL10 and IL12 signaling. Common TYK2 variants are also associated with Crohn's disease 28 and psoriasis 29 . A different, rare TYK2 variant, rs34536443, is associated with multiple sclerosis 30 . IL6 signaling through IL6R has diverse proinflammatory effects. In com bination with transforming growth factor (TGF)β, it influences the ratio of T H 17 to regulatory T (T reg ) cells, promoting the differentiation of T H 17 cells from naive T cells and inhibiting TGFβ-induced differ entiation into T reg cells 31 . Previous studies have reported no increase in T H 17 lymphocyte counts in ankylosing spondylitis, suggesting that the IL6R association with ankylosing spondylitis operates through mechanisms other than effects on T H 17 lymphocytes 32, 33 . Whether IL6 has a role in the differentiation or activation of noncanonical cellular sources of IL17 such as γδ T cells, NK cells, neutrophils and mast cells, which have been implicated in ankylosing spondylitis, is unclear. IL27 potentiates the differentiation of CD4 + T H 1 cells, while suppressing the differentiation of T helper 2 (T H 2) and T H 17 cells. IL27 has previously been associated with both Crohn's disease and type 1 diabetes (Supplementary Table 8) , with the association in type 1 diabetes being in the opposite direction to that observed in both ankylosing spondylitis and Crohn's disease.
At IL23R, we identified rare variant associations with ankylosing spondylitis in addition to the two known common variant haplotypes at this locus. Although one of these haplotypes has been shown to be due to association with the rs11209026 coding SNP 6,25 , it is not clear from these genetic studies whether the second haplotype tagged by the intergenic SNP rs12141575 influences ankylosing spondylitis through effects on IL23R or IL12RB2. IL12RB2 encodes one of the two subunits of IL12R, the stimulation of which drives CD4 + lym phocyte differentiation toward the T H 1 lineage and away from the T H 17 lymphocyte phenotype.
We identified six ankylosing spondylitis-associated genes that were also associated either with variation in CD8 + lymphocyte counts (EOMES, IL7R, RUNX3 and ZMIZ1) or CD4 + lymphocyte counts (BACH2 and SH2B3). EOMES encodes eomesodermin, a transcrip tion factor involved in CD8 + T cell differentiation whose expression is induced by . Where eomesodermin is deficient, CD8 + T cells have been shown to express IL17 (ref. 37). IL7 acts through IL7R to induce RUNX3 expression in developing T cells, in turn favoring differentiation toward the CD8 + T cell lineage 38 . ZMIZ1 is a transcriptional coactivator of the protein inhibitor of activated STAT (PIAS)like family and thus may have effects on STATmediated cytokine signaling. ZMIZ1 has recently been shown to cooperate with activating NOTCH1 mutations in inducing T cell acute lymphoblastic leukemia, consistent with it having a role in T cell differentiation 39 . Whether these genes affect risk of ankylosing spondylitis directly through effects on CD8 + T cell differentiation is unclear. For example, although the risk haplotype at RUNX3 is associated with lower CD8 + T cell counts, at IL7R, the opposite phenotype is observed, suggesting that the mechanisms involved are more complex than a simple effect on CD8 + T cell counts. IL7 treatment has been shown to increase T H 17 lymphocyte counts, and it may be that the association of IL7R with ankylosing spondylitis operates directly through such an effect 40 .
One of the genes associated with both ankylosing spondylitis and CD4 + lymphocyte counts, BACH2, encodes a B cell-specific transcrip tion factor with diverse effects on B cell differentiation and function 41 ; association of ankylosing spondylitis with CD4 + lymphocyte counts may thus be an indirect effect mediated by B cells. This is particu larly noteworthy given the recent evidence suggesting that rituximab, a B cell-targeted therapy, may have beneficial effects in ankylosing spondylitis 42 . SH2B3 (also known as LNK) encodes an adaptor pro tein involved in T cell receptor signaling 43 . CD8 + lymphocytes are activated by the interaction of MHC class I peptides with their T cell receptors and may in turn become cytotoxic or memory T cells.
The association of four aminopeptidases involved in peptide trim ming before HLA class I presentation is particularly noteworthy. We have shown here and previously that genetic variants associated with reduced function of ERAP1 and loss of expression of ERAP2 are pro tective for ankylosing spondylitis. Whether LNPEP is also involved is uncertain, and identification of the key associated variants at NPEPPS will require further studies. It is possible that these genes operate in ankylosing spondylitis through a quantitative effect on HLA class I peptide presentation or a qualitative effect on the peptide reper toire presented. Downregulation of ERAP1 (refs. 44,45) and ERAP2 (ref. 19 ) expression has been shown to reduce cell surface expression of HLA class I molecules. ERAP1 preferentially cleaves hydrophobic amino acids, whereas ERAP2 preferentially cleaves basic residues. ERAP1ERAP2 heterodimers may thus act in concert, particularly in cleaving longer peptides 45 . It has been suggested that misfolding of nascent HLAB*27 in the ER, leading to ER stress, may be involved in the pathogenesis of ankylosing spondylitis 46 . It is also possible that, by influencing the quantity of peptide available during HLAB*27 folding, ERAP1 and ERAP2 variants associated with disease risk slow the rate of this folding, thereby increasing ER stress.
In this study, over onethird of loci with common variant associa tions were found to harbor more than one diseaseassociated haplo type. Identifying these additional haplotypes increased the proportion of genetic variance explained in ankylosing spondylitis and, more notably, led to valuable biological insights. For example, association of ankylosing spondylitis with SNPs on chromosome 12p13 has previ ously been reported, although it was not clear whether the association was primarily with TNFRSF1A or LTBR, both plausible candidate genes 6, 7, 47 . The current study shows that there are two signals at this locus, one in TNFRSF1A and the other in LTBR. The primary associ ated SNP at TNFRSF1A (rs1860545) is in strong LD with a multiple sclerosis-associated SNP, rs1800696 (r 2 = 0.96, D′ = 0.98) but with the opposite direction of association. rs1800696 has recently been shown to lead to the splicing out of exon 6 of TNFR1, resulting in loss of the transmembrane domain 48 . The resulting protein acts as a soluble decoy receptor for TNF, akin to the TNF inhibitor drug etanercept. TNF inhibitors are highly effective therapeutic drugs in ankylosing spondylitis, but their use can lead to induction or exacerbation of multiple sclerosis. The association with ankylosing spondylitis sug gests the possibility that disease activity and response to TNF inhibi tor therapy may be affected by this SNP.
Comparison of the genetic associations of ankylosing spondylitis with other diseases reinforces the considerable overlap with Crohn's disease, ulcerative colitis and ankylosing spondylitis. Ankylosing spondylitis frequently complicates inflammatory bowel disease (both Crohn's disease and ulcerative colitis), and increased cofamili ality with inflammatory bowel disease has been demonstrated 49,50 , npg A r t i c l e s suggesting shared etiopathogenesis. Overlapping genetic susceptibil ity between ankylosing spondylitis and inflammatory bowel disease has previously been reported 51, 52 . The genes involved include many with effects on the IL23 pathway, supporting the notion of this being a key pathway in the pathogenesis of these conditions, most likely through effects on gut mucosal immunology. However, the major loci for each disease are not shared, with ankylosing spondylitis showing no association with NOD2 or ATG16L1 and neither Crohn's disease nor ulcerative colitis showing association with HLA-B*27. This sug gests that these diseasespecific loci contribute to the organ and tissue specificity of the diseases with which they are associated, whereas the IL23 pathway is involved in the core immunological pathway underlying all these conditions.
We also identified associations with three loci encoding G proteincoupled receptors, including GPR35, GPR37 and GPR65, and a fourth (GPR25) is close to KIF21B, an established ankylosing spondylitis locus where the key associated variants are not yet defined. The func tions of these genes and their ligands are not well established. GPR35 is reported to act as a receptor for 2acyl lysophosphatidic acid, and GPR65 is reported to be a receptor for glycosphingolipids and pro tons; the ligands for GPR25 and GPR37 are not known. GPR65 has previously been associated with Crohn's disease 53 and multiple sclero sis 54 . The mouse homolog of GPR65, T cell death-associated gene 8, inhibits proinflammatory cytokine production (including of TNFα and IL6) in acidic conditions 55 , suggesting a potential mechanism in diverse autoimmune diseases. However, it also has antiapoptotic effects and an ability to activate not only cyclic AMP (cAMP) intracel lular signaling but also other pathways, including mitogenactivated protein kinase (MAPK) and MEK/ERK signaling and thus is likely to have multiple functions 56 . Further research is needed into the func tions of these genes and their roles in autoimmune diseases.
It has long been suspected that associations in the MHC region with ankylosing spondylitis are not completely explained by HLA-B*27. The association of HLA-A*0201 with ankylosing spondylitis at genomewide significance in both HLA-B*27-positive and HLA-B*27-negative cases confirms that suspicion. HLA-A*02 has previously been reported to be associated with anterior uveitis complicating ankylosing spondylitis 57 and is a risk factor for vitiligo 58 . HLA-A*0201 has a protective effect in multiple sclerosis 54 and is a risk allele for type 1 diabetes 59 , but no HLA-A association has previously been reported with ankylosing spondylitis itself.
In conclusion, we have increased the number of ankylosing spond ylitis-associated loci to 31, identifying 13 new loci and 12 additional ankylosing spondylitis-associated haplotypes at 11 loci, bringing the total number of genetic signals independently associated with anky losing spondylitis to 43. These loci reinforce the mounting evidence that aberrant peptide processing before MHC class I presentation and alterations of the IL23 pathway are key elements in the pathogenesis of ankylosing spondylitis.
URL. Haploxt, http://genome.sph.umich.edu/wiki/Haploxt.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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